Compare SNEX & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNEX | PTCT |
|---|---|---|
| Founded | 1924 | 1998 |
| Country | United States | United States |
| Employees | 5400 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.5B |
| IPO Year | 1996 | 2006 |
| Metric | SNEX | PTCT |
|---|---|---|
| Price | $77.76 | $66.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 16 |
| Target Price | ★ $81.33 | $80.94 |
| AVG Volume (30 Days) | 512.3K | ★ 959.7K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | 2.50 | ★ 7.78 |
| Revenue | ★ $132,378,200,000.00 | $264,734,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.69 | $19.30 |
| P/E Ratio | $31.11 | ★ $8.61 |
| Revenue Growth | 32.53 | ★ 36.19 |
| 52 Week Low | $65.58 | $35.95 |
| 52 Week High | $132.57 | $87.50 |
| Indicator | SNEX | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 27.64 | 47.92 |
| Support Level | N/A | $61.43 |
| Resistance Level | $97.49 | $69.29 |
| Average True Range (ATR) | 3.83 | 2.35 |
| MACD | -3.43 | 0.38 |
| Stochastic Oscillator | 21.15 | 50.28 |
StoneX Group Inc is a Global brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, Global payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.